Efficacy and safety of autologous hematopoietic stem cell transplantation in elderly multiple myeloma patients: a single center retrospective study.
10.3760/cma.j.issn.0253-2727.2022.02.009
- Author:
Bei Hui HUANG
1
;
Juan LI
1
;
Wai Yi ZOU
1
;
Jun Ru LIU
1
;
Jing Li GU
1
;
Xiao Zhe LI
1
;
Mei Lan CHEN
1
;
Li Fen KUANG
1
Author Information
1. First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
- Publication Type:Journal Article
- Keywords:
Autologous transplantation;
Elderly;
Multiple myeloma;
Toxicity;
Treatment efficacy
- MeSH:
Aged;
Hematopoietic Stem Cell Mobilization/methods*;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Humans;
Multiple Myeloma/drug therapy*;
Retrospective Studies;
Transplantation, Autologous/methods*;
Treatment Outcome
- From:
Chinese Journal of Hematology
2022;43(2):141-145
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (auto-HSCT) in elderly patients (≥65 years old) with multiple myeloma (MM) . Methods: From June 1, 2006 to July 31, 2020, 22 MM patients (≥65 years old) who were diagnosed in the First Affiliated Hospital, Sun Yat-sen University and received novel drug induction followed by auto-HSCT were analyzed retrospectively. These patients were evaluated for important organ functions before transplantation, and the International Myeloma Working Group frail score was used in 2016 to screen out transplant-eligible patients. Results: The median (interquartile range, IQR) age at the time of transplantation of the 22 patients was 66.75 (IQR 4.50) years. A total of 20 patients received stem cell mobilization. The median number of mononuclear cells collected was 4.53×10(8)/kg, that of CD34(+) cells was 3.37×10(6)/kg, and the median number of apheresis procedures performed was 2. After stem cell transfusion, the median time of neutrophil implantation was 11 days, that of platelet implantation was 13 days, and the treatment-related mortality was 0 at 100 days after transplantation. The median follow-up was 48.7 months. The median time to progression time was not reached, and the median overall survival time was 111.8 months. Conclusion: Auto-HSCT is a safe and effective treatment for selected elderly patients of 65 years or older with MM.
